IXT-008

IXT-008 is an investigational inhalation therapy being developed by invoX Pharma for the treatment of pulmonary arterial hypertension (PAH). The drug is formulated for delivery via the proprietary Softhaler® platform, which is described as a dry powder inhalation system designed to provide high-efficiency delivery of medications to the deep lung with low inspiratory effort. While the specific active pharmaceutical ingredient and molecular target have not been publicly disclosed, the program is part of invoX's pipeline focused on respiratory and pulmonary vascular diseases. IXT-008 is currently in the early stages of development and represents the company's effort to leverage advanced inhalation technology for the treatment of complex pulmonary conditions.

Other names

iloprost inhalation powder